Barecetamab (Anti-ERBB3/HER3) is a fully human antibody directed against the receptor tyrosine-protein kinase erbB-3 (ErbB3; HER3) with antineoplastic activity. It has the potential to be used in research on recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). MW: 137.96 KD.